Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Truist Financial Analyst Says

Dianthus Therapeutics (NASDAQ:DNTH) had its target price upped by equities research analysts at Truist Financial from $110.00 to $128.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 18.89% from the stock’s previous close.

Several other analysts also recently issued reports on DNTH. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright upped their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Stock Performance

Shares of DNTH traded down $4.84 during midday trading on Thursday, hitting $107.66. 240,958 shares of the stock traded hands, compared to its average volume of 973,844. The business’s 50 day moving average price is $94.02 and its two-hundred day moving average price is $79.98. The firm has a market capitalization of $5.89 billion, a PE ratio of -26.01 and a beta of 1.22. Dianthus Therapeutics has a 1-year low of $18.08 and a 1-year high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 25.73%. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. As a group, equities research analysts forecast that Dianthus Therapeutics will post -3.82 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 87,779 shares of company stock worth $7,985,235 over the last three months. Company insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Walleye Capital LLC acquired a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $1,743,000. Handelsbanken Fonder AB acquired a new position in shares of Dianthus Therapeutics during the second quarter worth about $1,491,000. Assenagon Asset Management S.A. bought a new position in shares of Dianthus Therapeutics during the second quarter worth about $27,358,000. Seven Fleet Capital Management LP grew its holdings in shares of Dianthus Therapeutics by 451.6% during the first quarter. Seven Fleet Capital Management LP now owns 80,809 shares of the company’s stock worth $6,781,000 after buying an additional 66,158 shares in the last quarter. Finally, DV Trading LLC acquired a new stake in Dianthus Therapeutics in the 1st quarter valued at approximately $2,228,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.